Drug firm Caplin Point Laboratories Monday said its subsidiary has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable portfolio.
As a part of the deal, Caplin Steriles, a wholly owned subsidiary of Caplin Point Laboratories Ltd, will out-license five of its injectable Abbreviated New Drug Applications (ANDAs) to Baxter Healthcare Corporation.
"Caplin Steriles Ltd has entered into a license and supply agreement with Baxter Healthcare Corporation for five generic injectable ANDAs," Caplin Point Laboratories said in a regulatory filing.
Specific terms of the agreement and financial details, however, were not disclosed.
"All these ANDAs have been developed in-house, and we are keen to license them to Baxter, who have an excellent sales and marketing infrastructure in the US for commercialisation of these products," Caplin Point Laboratories Chairman C C Paarthipan said.
Shares of Caplin Point Laboratories were trading 2.36 per cent higher at Rs 396.45 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)